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Abstract 
 
Purpose: Although ~25% of colorectal cancer or polyps (CRC/P) cases show familial 
aggregation, current germline genetic testing identifies a causal genotype in the 16 major genes 
associated with high penetrance CRC/P in only 20% of these cases. As there are likely other 
genes underlying heritable CRC/P, we evaluated the association of variation at novel loci with 
CRC/P. 
Methods: We evaluated 158 a priori selected candidate genes by comparing the number of rare 
potentially disruptive variants (PDVs) found in 84  CRC/P cases without an identified CRC/P 
risk associated variant and 2440 controls. We repeated this analysis using an additional 73 
CRC/P cases. We also compared the frequency of PDVs in select genes among CRC/P cases 
with two publicly available data sets. 
Results: We found a significant enrichment of PDVs in cases versus controls: 20% of cases vs. 
11.5% of controls with ≥ 1 PDV (OR=1.9, p=0.01) in the original set of cases. Among the 
second cohort of CRC/P cases, 18% had a PDV, significantly different from 11.5% (p=0.02). 
Logistic regression, adjusting for ancestry and multiple testing, indicated association between 
CRC/P and PDVs in NTHL1 (p=0.0001), BRCA2 (p=0.01) and BRIP1 (p=0.04). However, there 
was no significant difference in the frequency of PDVs at each of these genes between all 157 
CRC/P cases and two publicly available data sets.  
Conclusion: These results suggest an increased presence of PDVs in CRC/P cases and support 
further investigation of the association of NTHL1, BRCA2 and BRIP1 variation with CRC/P. 
Key words: Colorectal cancer/polyps; genetic testing panels; BRIP1; NTHL1; BRCA2  
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INTRODUCTION 
Colorectal cancer (CRC) is the third most common and second most lethal cancer in the United 
States(Howlader et al. 2016). In 2016, CRC was estimated to be newly diagnosed in ~134,000 
individuals in the United States(Howlader et al. 2016). The lifetime risk of developing CRC is 
~4.5%(Howlader et al. 2016). Without CRC screening, this risk doubles for individuals with a 
single affected first-degree relative, and increases further with additional affected first-degree 
relatives (Fuchs et al. 1994, 1669-1674). At present, about 5% of all CRC cases can be attributed 
to a pathogenic variant in genes known to be associated with increased CRC risk(Patel and 
Ahnen 2012, 428-438). 
There are several high penetrance Mendelian genes whose germline variants are known to be 
associated with CRC, which generally develops from adenomatous polyps or serrated polyps 
(Levin et al. 2008, 130-160). Most of these conditions have an autosomal dominant mode of 
inheritance. Approximately 20% of CRC and/or adenomatous polyps (CRC/P) patients who have 
an identified pathogenic variant are diagnosed with Lynch syndrome [MIM 120435], which is 
caused by pathogenic variants in the mismatch repair genes MSH2[MIM 609309], MLH1[MIM 
120436], PMS2[MIM 600259] and MSH6[MIM 600678] or epigenetic silencing of MSH2 
through deletion in the 3’ exons of EPCAM [MIM 185535](Lynch and de la Chapelle 1999, 801-
818; Ligtenberg et al. 2009, 112-117). Other autosomal dominant syndromes with high risk of 
CRC/P include familial adenomatous polyposis, distinguished by >100 to thousands of colorectal 
adenomatous polyps [MIM 175100] (APC [MIM 611731]), Li-Fraumeni [MIM 151623] (TP53 
[MIM 191170]), juvenile polyposis [MIM 174900] (SMAD4 [MIM 600993], BMPR1A [MIM 
601299]),  Peutz-Jeghers syndrome [MIM 175200] (STK11[MIM 602216]), as well as PTEN 
[MIM 601728], AKT1 [MIM 164730], and PIK3CA [MIM 171834] (Nishisho et al. 1991, 665-
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669; Malkin et al. 1990, 1233-1238; Jenne et al. 1998, 38-43). Pathogenic variants that 
predispose to CRC/P have also been identified in POLE [MIM 174762] and POLD1 [MIM 
174761] (Palles et al. 2013, 136-144) and are inherited in an autosomal dominant pattern. 
Recessive mode of inheritance of CRC/P is attributable to pathogenic variants in MUTYH [MIM 
604933], associated with tens to hundreds of polyps and possibly the more recently reported 
NTHL1 [MIM 602656] and MSH3 (Jones et al. 2002, 2961-2967; Weren et al. 2015, 668-671; 
Adam et al. 2016, 337-351).    
In addition to the 5% of CRC/P cases that can be explained by a germline pathogenic variant, 
another ~20-25% of all CRC/P cases appear familial, but do not have a causal variant identified 
by current genetic testing (Lynch and de la Chapelle 1999, 801-818; Patel and Ahnen 2012, 428-
438; PDQ Cancer Genetics Editorial Board 2002). Failure to detect a genetic etiology for these 
patients may be due to one of several reasons. First, the underlying cause may be sporadic in 
multiple relatives, rather than hereditary (Lichtenstein et al. 2000, 78-85), resulting in 
phenocopies. Second, germline genetic panel testing may detect variants of uncertain 
significance (VUS) which are truly pathogenic, but their pathogenicity is not yet established. 
Third, technical issues may result in a false negative genetic finding. Fourth, low penetrance 
common variants account for some portion of CRC/P (Peters et al. 2012, 217-234; Hes et al. 
2014, 55-60). Finally, as pathogenic variants in other known cancer associated genes from 
broader panels have been found in such patients, there may be other highly penetrant pathogenic 
variants in genes underlying heritable CRC/P that have not been identified or validated and are 
not included on current CRC/P specific genetic testing panels (AlDubayan et al. 2018, 401-414).  
Several thousand genes have been proposed to be involved in CRC/P risk. These include genes 
involved in DNA repair pathways and other cancer related biological pathways, and genes 
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implicated by GWAS or familial linkage (Hes et al. 2014, 55-60; Gylfe et al. 2013, e1003876; 
Smith et al. 2013, 1026-1034). We set out to narrow this list of candidate genes to test for 
evidence of novel CRC/P associated genes. Identification of such genes would allow for 
improved diagnostic testing using evolving CRC/P germline genetic testing panels.  
MATERIALS AND METHODS 
Participants – Original Cohorts 
Ninety-two participants with CRC/P and of European ancestry (EA) were ascertained from three 
sources: The Clinical Sequencing Exploratory Research consortium, New EXome Technology in 
Medicine study (CSER) (N=57) at the University of Washington (UW), the Northwest Institute 
of Genetic Medicine Family Polyps Study (PP) (N=10) at UW, and the Women’s Health 
Initiative (WHI) (N=25). Participants from CSER and PP were ascertained through referral to the 
UW Genetic Medicine clinic and will be referred to jointly as UW participants. These patients 
were referred for clinical genetic counseling and genetic testing and tended toward early age of 
onset of CRC/P or a positive family history. The parent CSER study on high throughput 
sequencing of CRC/P patients did not enroll individuals for whom  clinical usual care 
recommendations were to pursue a single gene test, rather than a broader gene panel (Gallego et 
al. 2016, 515-519). Research on these cases was approved by the biomedical IRB committee at 
the UW and participants granted permission for broad sharing of genomic and phenotypic data 
by informed consent documentation. WHI participants were ascertained through the 
observational WHI study(The Women’s Health Initiative Study Group 1998, 61-109). Case 
status was defined as having a diagnosis of CRC before age 65 (UW, WHI), and/or ≥10 
adenomatous polyps (lifetime total) (UW only) (Table 1). A convenience sample of 2512 EA 
control participants (ESP) was ascertained from the NHLBI GO Exome Sequencing Project (See 
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web resources) (Amendola et al. 2015, 305-315). Individuals younger than 30 or with body mass 
index (BMI) > 50 were excluded as CRC/P rarely presents before age 30 and high BMI is 
associated with an increased risk for CRC/P. BMI ranged between 15 and 49.8 with a mean of 
27.6. Cancer and polyp phenotypes for these ESP control individuals was unknown, therefore it 
is possible that some have a history of CRC/P. Demographic information for the controls is given 
in Table 1.  
Participants – Subsequent Cohorts 
A second cohort of deceased EA CRC patients was ascertained through the ColoCare study 
(CoCa, N=73) (Yuan et al. 2017, 1202-1210). These patients were newly diagnosed between the 
ages of 18 and 80, and had not had genetic testing (Table 1).  
For further comparison, we used two additional, publicly available data sets.  We used a cohort 
consisting of 7325 EA women from the FLOSSIES data set (see web resources) (Walsh et al. 
2010, 12629-12633; Wang et al. 2015, 926-937; Li et al. 2008, 1100-1104). These women were 
over 70 years of age, had no history of a cancer diagnosis and were sequenced for genes on the 
BROCA panel, which includes genes known to be associated with CRC/P as well as genes 
associated with breast, ovarian, prostate, pancreatic, and renal cancers (Walsh et al. 2010, 12629-
12633; Walsh et al. 2011, 18032-18037; Nord et al. 2011, 184; Metzker 2010, 31-46; Shirts et al. 
2016, 974-981). Additionally, we used frequency summary data from the Exome Aggregation 
Consortium (ExAC), with the Cancer Genome Atlas  (TCGA) subset removed (non-TCGA-
ExAC) (see web resources). This data set consists of 53,105 individuals (27,173 EA) with whole 
exome data, who were ascertained at multiple sites for many different traits, excluding 
individuals from TCGA (Lek et al. 2016, 285-291). We used these cohorts and the cases to 
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perform one-sided Fisher exact tests comparing the expected frequency of PDVs for some of the 
genes of interest.  
Next Generation Sequencing and Genotype Calling 
Cases were sequenced on Roche NimbleGen SeqCap EZ v3 (UW, CoCa) and Agilent SureSelect 
All Exon v5 (WHI). ESP Controls were sequenced on Agilent SureSelect Human All Exon Kit 
v2, Nimblegen RefSeq/CCDS design, or SeqCap EZ v1, divided among two centers: BROAD 
(N=1122) and Nickerson UW lab (N=1390). As the target regions differed, we focused attention 
on the regions covered by all targets. In order to avoid an effect of different sequencing centers 
used for the UW/WHI cases and ESP controls, on the analysis, we only included variants that 
were genotyped in >90% of the participants and had depth of coverage >20 for at least 80% of 
the participants. The UW/WHI cases and ESP control genotypes were jointly called, 
simultaneously, using Genome Analysis Toolkit (McKenna et al. 2010, 1297-1303; Van der 
Auwera, G A et al. 2013, 33; Poplin et al. 2017). Details of the genotyping and quality controls 
methods are in the supplemental methods. Individual level quality control measures resulted in 
removal of 18 ESP controls from the analysis, leaving 2494 ESP controls. The resulting, filtered, 
high confidence genotype data was annotated using SeattleSeqAnnotation138 (Ng et al. 2009, 
272-276; Lek et al. 2016, 285-291). Further annotation was obtained from ClinVar and HGMD 
(Stenson et al. 2009, 13; Landrum et al. 2016, 862). Variants were determined to be pathogenic 
or likely pathogenic by expert panel, using the American College of Medical Genetics and 
Genomics guidelines and clarifications from Amendola et al. (Richards et al. 2015, 405-424; 
Amendola et al. 2015, 305-315). Eight UW/WHI case subjects (8.7%) and 54 ESP controls 
(2.2%) were removed from analysis due to having a known pathogenic or likely pathogenic 
variant in any of the following 16 genes known to be associated with increased CRC/P risk: 
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TP53, PTEN , MSH2, MLH1, MSH6, PMS2, EPCAM , APC, MUTYH, STK11, SMAD4, 
BMPR1A, POLE, POLD1, AKT1, and PIK3CA (Supplemental Table 1).  Individuals 
heterozygous for a pathogenic variant in MUTYH, which is associated with autosomal recessive 
disease, were also excluded, in case a second pathogenic variant at this gene was missed. We did 
not evaluate the CHEK2 gene [MIM 604373] as it has low penetrance for CRC/P (Naseem et al. 
2006, 388-395).   A total of 84 UW/WHI cases and 2440 ESP controls remained in the initial 
analysis. Of these, 15 UW/WHI cases (16%) and 604 ESP controls (25%) had a VUS in a known 
CRC/P gene (Supplemental Table 2). European ancestry of all cases was confirmed using 
principal components analysis (PCA) (see Supplemental Methods).  
The same methods for joint genotyping, quality control, and confirmation of EA ancestry were 
used on the second case cohort. As the exome sequences for the CoCa cases were collected at a 
much later date, their genotypes were called separately from the first set of cases and the ESP 
controls. All 73 CoCa cases passed quality control and none of them harbored a pathogenic 
variant in any of the 16 known CRC/P genes listed above. Nineteen CoCa cases had at least one 
VUS in the 16 known CRC/P genes (Supplemental Table 2). 
 
Genes and Variation of Interest 
We focused the enrichment analysis on 158 genes collected from multiple sources and with 
varying supportive evidence for a role in CRC/P (Supplemental Table 3). This evidence derives 
from GWAS tagging SNPs (N=12), loss of function and linkage (N=12), known somatic 
involvement (N=2), or involvement in DNA repair pathways according to(Smith et al. 2013, 
1026-1034) (N=133). Several of these genes are a priori known to be associated with other 
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cancers. It is expected that those genes that have evidence derived from linkage or are involved 
in other cancers are more likely candidates. However, we chose to keep a broader set of genes to 
allow for lower penetrance genes. We limited our analyses to potentially disruptive variation 
(PDV) to focus on the most relevant variants, which may increase power to detect an effect. We 
defined a PDV as having a minor allele frequency (MAF) < 0.005 in the ESP controls and all 
published populations in gnomAD (Lek et al. 2016, 285-291) (See Web Resources), and to likely 
cause a change in the protein product, such as a stop gain (SG), frameshift (FS), splice acceptor 
(SA) or splice donor (SD) change. Early terminations (SG, FS) that resulted in a termination 
codon within 50 base pairs of the 3’ end of the penultimate exon, or occurred within the last 
exon, were excluded from the analysis as they are expected to result in a functional protein.   
Statistical Methods 
We took a step-wise approach to testing for enrichment of PDVs in the 158 tested genes among 
the UW/WHI cases versus the ESP controls. First, we performed a global, one-sided test across 
all the considered genes, to test the alternative hypothesis that the number of PDV heterozygotes 
in UW/WHI cases would be higher than in the ESP controls. Second, we compared the 
distribution of the coding changes between these cases and controls. Finally, we used logistic 
regression to perform one-sided burden tests for each gene, adjusting for the first 5 principal 
components of ancestry (PCs) (see Supplemental Methods).  We used a Bonferroni correction to 
determine significance for single gene comparisons.  
We further tested the alternative hypothesis that the overall frequency of PDV heterozygotes in 
the second case cohort (CoCa) would be higher than the frequency found in the ESP controls, 
above. In this situation, we are not accounting for the variation in the estimated frequency in the 
controls, and are assuming the estimate is representative of EA individuals, in general.  
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Finally, we  compared the frequency of PDVs in specific genes in all cases to the observed total 
frequency of PDVs in EA cohorts from the FLOSSIES and non-TCGA Exac data sets using 
Fisher’s exact test. All statistical analyses were performed using the R 3.1.0 package(R Core 
Team 2016). All tests are one-sided, unless otherwise indicated. 
RESULTS 
PDVs in UW/WHI cases vs. ESP controls  
The UW/WHI cases had a statistically significant greater proportion of PDV heterozygotes in the 
genes tested than the ESP controls, with an odds ratio (OR) of 1.9, 95% C.I. (1.2, ∞) (one-sided 
Fisher’s exact test p-value = 0.02). Specifically, 17 cases (20%) had a PDV in a total of 16 genes 
(Table 2). One case had two PDVs: one in BRCA2 [MIM 600185] and one in NTHL1. The same 
PDV in NTHL1, rs150766139, was found in 2 separate cases. Two genes, POLQ [604419] and 
RECQL [600537], had two unique PDVs each in the cases. In contrast, only 11.5% of controls 
(N=282) had a PDV in a total of 84 genes (Supplemental Table 4). Seventeen controls had two 
PDVs each, and 49 genes had multiple PDVs in the controls (Supplemental Figure 1). The 
NTHL1 PDV observed in 2 cases (2.4%), rs150766139, was found in 4 controls (0.16%). Both 
RECQL variants observed in the cases were each seen in a control (0.04%) and one POLQ 
variant observed in the cases (NM_199420.3:c.2021dupA) was seen in one control (0.04%).  
Sensitivity analyses removing splice variants from the analysis gave similar results (OR = 2, 
95% C.I. (1.1, ∞), p = 0.02), as did reducing the MAF cutoff to 0.001 (OR=2, 95% C.I. (1.1, ∞), 
p=0.01).  
A total of 237 unique PDVs (93 FS; 99 SG; 20 SA; 25 SD) were observed in the UW/WHI cases 
and ESP controls in 84 (53%) genes. Although the cases have a higher proportion of FS than the 
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controls (Supplemental Table 5), the distribution of PDV types is not statistically significantly 
different between cases and controls (p > 0.5). Seven PDVs (3 FS, 3 SG, 1 SD) were observed in 
both cases and controls.  
PDVs in CoCa cases  
Thirteen CoCa cases (18%) were heterozygous for a PDV, which is statistically significantly 
different from the 11.5% observed in the ESP controls (t-test p=0.02, Table 3). Of these 13 
PDVs (6 FS; 6 SG; 1 SA) the POLK frameshift, NM_016218.2:c.1243delA, was also observed in 
the UW/WHI cases and in seven ESP controls.   
Single gene tests in the UW/WHI cases and ESP controls 
There were 16 genes with PDVs in the UW/WHI cases; we performed logistic regression 
analyses between the UW/WHI cases and ESP controls for each. Three genes were significantly 
associated with case status, adjusting for multiple testing using a Bonferroni correction: NTHL1 
(p=0.0001), BRCA2 (p = 0.01) and BRIP1 (p = 0.04). One gene, RECQL, had suggestive 
evidence for association with case status, based on unadjusted p-value of 0.02 (Bonferroni 
corrected p = 0.15). In all models, the first 5 PCs, were significant with difference in deviance of 
327.77 on 5 degrees of freedom (χ2-test p < 2e-16, ). 
Single gene tests in all cases vs FLOSSIES and ExAC controls 
We further compared the frequency of PDVs at seven genes among all cases (UW/WHI/CoCa) 
with that observed in the FLOSSIES and non-TCGA ExAC data (Table 4). This list of genes 
included BRIP1 and genes with at least two heterozygous cases and no, or few, heterozygous 
ESP controls. The total frequency of PDVs was not significantly higher in the cases than the 
Flossies or ExAC controls, for any single gene, under the assumption that the PDVs are 
independent of each other within each gene.  
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Non-CRC/P Actionable Findings 
As the list of 158 genes studied here contains genes known to be associated with other cancers, it 
was possible to identify individuals heterozygous for a pathogenic or likely pathogenic variant in 
such genes (Tables 2 and 3, Supplemental table 4). This list of subjects includes 3 UW/WHI 
cases (ATM, BRCA2, BRIP1), 2 CoCa cases (BRCA2, FANCM) and 20 ESP controls (ATM, 
BRCA1, BRCA2, BRIP1, NBN).   
DISCUSSION 
Overall, both the UW/WHI and CoCa CRC/P case cohorts carried a significantly higher fraction 
of PDVs than controls in the 158 genes hypothesized to be associated with CRC/P. Three genes 
(NTHL1, BRCA2, and BRIP1) had variants associated with case status, adjusting for ancestry 
principal components and multiple testing. Support for an association between NTHL1 and 
CRC/P via a recessive mode of inheritance was reported by others during the course of this study 
(Weren et al. 2015, 668-671; Helgason et al. 2015, 906-910). Perhaps incidentally, a known 
BRCA2 pathogenic variant was identified in one of the two cases in our study with a PDV in 
NTHL1. Overall, our study supports the association of NTHL1 with CRC/P, but our design does 
not address mode of inheritance.  Interestingly, both BRCA2 and BRIP1 are associated with 
increased breast and/or ovarian cancer risk (Rafnar et al. 2011, 1104-1107; Ford and others 1998, 
676-689; Antoniou et al. 2003, 1117-1130), and we found pathogenic variants for these genes in 
one female with CRC/P (age at last evalutaion 49 years) without a personal history of either 
cancer, as well as in two males with CRC/P (ages at last evaluation 59 and 66 years). This 
suggests that these genes may be associated with a cancer syndrome that includes CRC/P, 
possibly at lower penetrance. In addition, we found a PDV in each of ATM and FANCM, two 
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genes known to be associated with autosomal dominant inheritance of breast cancer in two other 
CRC/P cases without a personal history of breast cancer: one male (age at last evaluation 75 
years) and one female (age at last evaluation 46 years), respectively (Swift et al. 1987, 1289-
1294; Kiiski et al. 2014, 15172-15177; Peterlongo et al. 2015, 5345-5355). These findings of an 
association with CRC/P for genes associated with breast and/or ovarian cancer are in alignment 
with that of AlDubayan et. al.. That study included a larger sample size and focused on a smaller 
set of genes known a priori to be associated with other heritable cancers and involved in DNA 
repair. In contrast, due to the small sample size of cases in our study, there is limited power to 
detect a significant difference in the frequency of PDVs for any single gene when comparing 
with the FLOSSIES or not-TCGA ExAC control data sets.  
In addition to the small number of cases, our study is limited by reduced power. First, several 
cases and controls that remained in the analysis had a VUS in a gene known to be associated 
with CRC/P; a subset of these variants may be pathogenic. Second, exome sequencing can detect 
point mutations and small indels, but cannot detect genetic rearrangements or interference from 
pseudoegenes. Therefore, our analysis may have not detected some pathogenic variants. Third, 
the ESP control participants, for whom we did not have phenotypes, and the non-TCGA ExAC 
data set likely included individuals with CRC/P or other cancers which lowered our power to 
detect a difference in the frequency of PDVs between cases and controls. To address this issue, 
we removed ESP control individuals with pathogenic variants in known CRC/P genes. However, 
we were unable to clean the ExAC data beyond removing the TCGA individuals. Fourth, the 
single gene tests may also be limited by lower penetrance, lowering the power of the tests. One 
future strategy to increase power to test these genes is to perform joint linkage and association 
family testing, adjusting for the presence of the proband, where family members are available.  
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This work demonstrates support for considering additional CRC/P associated genes be included 
in CRC/P gene mutation panel tests on a research basis. The authors caution that these genes 
should be considered as research genes, in the context of CRC/P, and should not be used to direct 
clinical care for CRC/P at this time. Given the expectation of high locus heterogeneity with many 
genes having an effect on CRC/P risk, larger studies will be required to determine which genes 
account for the observed excess of PDVs in CRC/P cases vs. controls identified here. 
Web Resources 
esp.gs.washington.edu/drupal/dbGaP_Releases 
https://whi.color.com/ 
ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3.1/subsets 
https://software.broadinstitute.org/gatk/documentation/article.php?id=3893 
http://gnomad.broadinstitute.org/ 
Supplementary information is available at the Human Gentics website. 
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Tables 
Table 1: Demographic data for cases and controls  
Cases N N Male (%) N Family 
History (%) 
Age range 
(mean) 
N CRC 
(%) 
N P 
(%) 
UW 67 39 (58) 44 (66) 18,64 (44) 39 (58) 46 
(69) 
WHI 25 0 (0) 25 (100) 55,64 (61) 25 (100) 1 (4) 
Total 92 39 (42) 69 (75) 18,64 (48) 64 (70) 47 
(51) 
CoCa 73 41 (56) UN 20,80 (57) 73 UN 
       
ESP 
Controls 
      
Nickerson 1390 681 (49) UN 30,92 (58) UN UN 
BROAD 1122 413 (37) UN 30,92 (56) UN UN 
Total 2512 1094 (44) UN 30,92 (57) UN UN 
Age is minimum age of diagnosis for CRC/P (UW, WHI, CoCa) or adenomatous polyps (UW) in cases 
and age of ascertainment for controls. N=count; CRC=colorectal cancer; P=any adenomatous polyps; 
UN=Unknown; UW=University of Washington samples (CSER and PP); WHI=Women’s Health 
Initiative samples; CoCa=ColoCare. 
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Table 2: Observed PDVs in suspected CRC/P genes in UW/WHI cases. Func=function. FS=frameshift. 
SG=stop gain. SA=splice acceptor. SD=splice donor. CRC=colorectal cancer, P=Polyps; Number of 
adenomas. Age=age at diagnosis. NC = number of ESP controls with the same variant. Variants in 
bold are known to be pathogenic for a different cancer. 
Gene Chr. Pos. rsID Func. HGVS-name Phenotype 
(Age) 
NC 
ATM 11 108216600 876658716 SG NM_000051.3:c.8549T>A P25(64) 0 
BRCA2 13 32932022 80359679 FS NM_000059.3:c.7762delA AP10 (34) 0 
BRIP1 17 59853848 NA FS NM_032043.2:c.2010dupT CRC/P>10 
(43) 
0 
CCDC18 1 93680404 NA SG NM_206886.3:c.1600C>T CRC (56) 0 
DCLRE1A 10 115601320 NA SA NM_001271816.1:n.3381G>A CRC (33) 0 
ERCC2 19 45855877 NA SG NM_000400.3:c.1933C>T P>14 (50) 0 
BNTHL1 16 2096239 150766139 SG NM_002528.5:c.268C>T AP10 (34);  4 
CRC (45) 
NUDT7 16 77759403 200408443 SG NM_001105663.2:c.111T>A CRC (40) 10 
PNKP 19 50365057 NA FS NM_007254.3:c.1253_1269dupGG
GTCGCCATCGACAAC 
P28 (30) 3 
POLK 5 74882863 NA FS NM_016218.2:c.1243delA P13 (58) 7 
POLQ 3 121186441 NA SG NM_199420.3:c.6892C>T CRC/P10 
(42) 
0 
POLQ 3 121217455 NA FS NM_199420.3:c.2021dupA P20 (44) 1 
RAD50 5 131895029 NA FS NM_005732.3:c.186delA CRC/P3 
(31) 
0 
RECQL 12 21624504 199925437 SG NM_002907.3:c.1525A>T P10 (58) 1 
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RECQL 12 21636367 376839517 SG NM_002907.3:c.643C>T CRC/P3 
(38) 
1 
TDG 12 104374735 NA FS NM_003211.4:c.478dup CRC (40) 0 
UACA 15 70957000 377649125 SD NM_001008224.1:c.4074+1G>A P100 (25) 1 
WRN 8 30921820 NA FS NM_000553.4:c.229dupG P23 (40) 0 
A: Observed in presence of another PDV in same individual 
B: Observed in two cases  
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Table 3: Observed PDVs in suspected CRC/P genes in CoCa cases. Func=function. FS=frameshift. 
SG=stop gain. SA=splice acceptor. SD=splice donor. Age=age at diagnosis of colorectal cancer. NC = 
number of ESP controls with the same variant. Variants in bold are known to be pathogenic for a 
different cancer. 
Gene Chr. Pos. rsID Func. HGVS-name Age NC 
ALKBH3 11 43905557 1.45E+08 SG NM_139178.3:c.208C>T 36 5 
BRCA2 13 32914766 11571658 FS NM_000059.3:c.6275_6276delTT 65 0 
CCDC18 1 93646368 NA FS XM_005270815.1:c.282_283delCT, 
XM_005270816.1:c.282_283delCT 
65 0 
ERCC3 2 1.28E+08 rs774261851 FS NM_000122.1:c.1757_1758delAG 48 0 
ERCC3 2 1.28E+08 NA SG NM_000122.1:c.1300G>T 76 0 
FANCM 14 45667921 1.45E+08 SG NM_020937.2:c.5791C>T 44 5 
LAMA5 20 60899562 NA SG NM_005560.4:c.5578C>T 76 0 
MSH4 1 76345740 rs751781089 FS NM_002440.3:c.1686delA 51 1 
NEIL1 15 75641315 rs528340029 FS NM_001256552.1:c.330_331insAGGC, 
NM_024608.3:c.72_73insAGGC 
53 9 
POLH 6 43555090 NA SG NM_006502.2:c.354C>G 50 0 
POLK 5 74882863 rs773201725 FS NM_016218.2:c.1243delA 69 1 
PRKDC 8 48826626 NA SA NM_001081640.1:c.2618-2A>G 60 0 
RAD50 5 1.32E+08 rs750586158 SG NM_005732.3:c.3598C>T 72 0 
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Table 4: Comparison of total frequency of PDV alleles between all cases with the FLOSSIES and non-
TCGA ExAC data sets. Q=total frequency of PDVs. N=number of individuals with data at each gene for 
the cases and Flossies data sets, and the minimum number of individuals for each gene in non-TCGA 
ExAC. P=unadjusted p-value  
Gene Qcases QFlossies  NFlossies  PFlossies Qexac  Nexac Pexac 
BRCA2 0.006 0.001  7325 0.08 0.002 18084 0.12 
BRIP1 0.003 0.0008  7325 0.22 0.0007 15371 0.21 
CCDC18 0.006 NA NA NA 0.002 17597 0.14 
ERCC3 0.006 NA NA NA 0.001 19517 0.05 
NTHL1 0.006 NA NA NA 0.003 16316 0.21 
RAD50 0.006 NA NA NA 0.002 23607 0.19 
RECQL 0.006 0.002 3646 0.1 0.002 23648 0.12 
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